Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:RVLP

RVL Pharmaceuticals (RVLP) Stock Price, News & Analysis

RVL Pharmaceuticals logo

About RVL Pharmaceuticals Stock (NASDAQ:RVLP)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$0.00
$0.19
52-Week Range
N/A
Volume
63.96 million shs
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

RVL Pharmaceuticals plc, a specialty pharmaceutical company, focuses on the development and commercialization of pharmaceutical products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas in the United States, Argentina, and Hungary. It is commercializing Upneeq (RVL-1201), an oxymetazoline hydrochloride ophthalmic solution, for the treatment of acquired blepharoptosis, or low-lying eyelid in adults. The company was formerly known as Osmotica Pharmaceuticals plc and changed its name to RVL Pharmaceuticals plc in January 2022. RVL Pharmaceuticals plc is headquartered in Bridgewater, New Jersey.

Receive RVLP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for RVL Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

RVLP Stock News Headlines

Raval ICS Ltd.
Buffett’s favorite chart just hit 209% – here’s what that means for gold
A Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the quiet buildup behind the scenes. Now, in just days, the floodgates are set to open. The greatest investor of all time is about to validate what Garrett Goggin has been saying for months: Gold is entering a once-in-a-generation mania. Front-running Buffett has never been more urgent — and four tiny miners could be your ticket to 100X gains.
RVLPQ RVL Pharmaceuticals plc
RVL Pharmaceuticals PLC RVLPQ
See More Headlines

RVLP Stock Analysis - Frequently Asked Questions

RVL Pharmaceuticals plc (NASDAQ:RVLP) issued its quarterly earnings results on Monday, March, 20th. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.15) by $0.03. The company earned $9.81 million during the quarter, compared to analysts' expectations of $12.10 million.

Based on aggregate information from My MarketBeat watchlists, some other companies that RVL Pharmaceuticals investors own include Avino Silver & Gold Mines (ASM), Avino Silver & Gold Mines (ASM), Cardiff Oncology (CRDF), Osmotica Pharmaceuticals (OSMT), AbCellera Biologics (ABCL), Amarin (AMRN) and Coda Octopus Group (CODA).

Company Calendar

Last Earnings
3/20/2023
Today
5/27/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:RVLP
Fax
N/A
Employees
125
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$49.72 million
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
106,504,000
Optionable
Optionable
Beta
N/A
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

This page (NASDAQ:RVLP) was last updated on 5/27/2025 by MarketBeat.com Staff
From Our Partners